The Prognostic Value of Blood Eosinophil Level in AECOPD is Influenced by Corticosteroid Treatment During Hospitalization

Overview

Journal J Inflamm Res

Publisher Dove Medical Press

Date 2023 Aug 9

PMID 37555013

Authors

Jiachen Li

Lirong Liang

Lin Feng

Siyu Cao

Yutong Samuel Cai

Xiaobo Li

Zhenbei Qian

Christopher E Brightling

Zhaohui Tong

Affiliations

Soon will be listed here.

Abstract

Purpose: Blood eosinophil is a promising biomarker for phenotyping patients with acute exacerbation of COPD (AECOPD). We aimed to evaluate the prognostic value of eosinophil on short- and long-term outcomes stratified by corticosteroid treatment among AECOPD inpatients.

Patients And Methods: In this retrospective cohort study, we included patients hospitalized for AECOPD from July 2013 to June 2021 in Beijing, China. Clinical data were collected from electronic medical records. The blood eosinophil count was measured within 24h after admission. Eosinophilic AECOPD was defined as having an eosinophil percentage ≥ 2%. The study outcomes were length of stay (LOS), treatment failure, and AECOPD readmission risk within 3 years of discharge. Multivariable models were used to analyze the associations between blood eosinophil count and outcomes stratified by corticosteroid treatment during hospitalization.

Results: A total of 2406 AECOPD patients were included. The median LOS of AECOPD patients was 10 (interquartile range: 8-14) days. The eosinophil percentage was negatively associated with LOS (P-trend=0.014). Compared with the non-eosinophilic AECOPD group, the eosinophilic group had a 58% lower risk of treatment failure (OR=0.42, 95% CI: 0.20-0.89) in patients treated with systemic corticosteroids, but no association was observed in those treated with inhaled corticosteroids (ICS) only (OR=0.95, 95% CI: 0.60-1.52). The eosinophilic group had an increased risk of 90-day re-admission in patients treated with ICS only (HR=1.51, 95% CI: 1.00-2.29), but not in patients treated with systemic corticosteroids during hospitalization (HR=0.67, 95% CI: 0.39-1.15). No statistically significant results were found for 180-day, 1-year, or 3-year readmission risk.

Conclusion: Elevated blood eosinophils in AECOPD were associated with shorter length of stay and improved response to treatment with systemic corticosteroids, but not inhaled corticosteroids. Our study suggested that a therapeutic approach of using systemic corticosteroid may benefit patients present with eosinophilic AECOPD.

Citing Articles

Post-pandemic seasonal dynamics of hospitalised COPD exacerbations and aetiologies in the COPD population.

Aung H, Aung A, McAuley H, Elneima O, Flynn C, Thornton T ERJ Open Res. 2024; 10(5).

PMID: 39351391 PMC: 11440372. DOI: 10.1183/23120541.00258-2024.

Comprehensive Nomograms Using Routine Biomarkers Beyond Eosinophil Levels: Enhancing Predictability of Corticosteroid Treatment Outcomes in AECOPD.

Feng L, Li J, Qian Z, Li C, Gao D, Wang Y J Inflamm Res. 2024; 17:1511-1526.

PMID: 38476472 PMC: 10929658. DOI: 10.2147/JIR.S450447.

Long- versus short-duration systemic corticosteroid regimens for acute exacerbations of COPD: A systematic review and meta-analysis of randomized trials and cohort studies.

Zhao Z, Lou O, Wang Y, Yin R, Gong C, Deng F PLoS One. 2023; 18(12):e0296470.

PMID: 38157362 PMC: 10756550. DOI: 10.1371/journal.pone.0296470.

References

Camp J, Cane J, Bafadhel M . Shall We Focus on the Eosinophil to Guide Treatment with Systemic Corticosteroids during Acute Exacerbations of COPD?: PRO. Med Sci (Basel). 2018; 6(3). PMC: 6163385. DOI: 10.3390/medsci6030074. View

Duman D, Aksoy E, Coban Agca M, Durmus Kocak N, Ozmen I, Akturk U . The utility of inflammatory markers to predict readmissions and mortality in COPD cases with or without eosinophilia. Int J Chron Obstruct Pulmon Dis. 2015; 10:2469-78. PMC: 4648601. DOI: 10.2147/COPD.S90330. View

Bafadhel M, McKenna S, Terry S, Mistry V, Pancholi M, Venge P . Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2012; 186(1):48-55. PMC: 3400995. DOI: 10.1164/rccm.201108-1553OC. View

Ko F, Chan K, Ngai J, Ng S, Yip W, Ip A . Blood eosinophil count as a predictor of hospital length of stay in COPD exacerbations. Respirology. 2019; 25(3):259-266. DOI: 10.1111/resp.13660. View

Choi J, Oh J, Lee Y, Hur G, Yong Lee S, Shim J . The association between blood eosinophil percent and bacterial infection in acute exacerbation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2019; 14:953-959. PMC: 6511627. DOI: 10.2147/COPD.S197361. View

Zhang J, Zheng J, Huang K, Chen Y, Yang J, Yao W . Use of glucocorticoids in patients with COPD exacerbations in China: a retrospective observational study. Ther Adv Respir Dis. 2018; 12:1753466618769514. PMC: 5961923. DOI: 10.1177/1753466618769514. View

Kolsum U, Southworth T, Jackson N, Singh D . Blood eosinophil counts in COPD patients compared to controls. Eur Respir J. 2019; 54(4). DOI: 10.1183/13993003.00633-2019. View

Jabarkhil A, Moberg M, Janner J, Petersen M, Jensen C, Henrik Aangquist L . Elevated blood eosinophils in acute COPD exacerbations: better short- and long-term prognosis. Eur Clin Respir J. 2020; 7(1):1757274. PMC: 7241534. DOI: 10.1080/20018525.2020.1757274. View

Kolsum U, Donaldson G, Singh R, Barker B, Gupta V, George L . Blood and sputum eosinophils in COPD; relationship with bacterial load. Respir Res. 2017; 18(1):88. PMC: 5422866. DOI: 10.1186/s12931-017-0570-5. View

10.

Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P . Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011; 184(6):662-71. DOI: 10.1164/rccm.201104-0597OC. View

11.

Bafadhel M, Greening N, Harvey-Dunstan T, Williams J, Morgan M, Brightling C . Blood Eosinophils and Outcomes in Severe Hospitalized Exacerbations of COPD. Chest. 2016; 150(2):320-8. DOI: 10.1016/j.chest.2016.01.026. View

12.

Vogelmeier C, Roman-Rodriguez M, Singh D, Han M, Rodriguez-Roisin R, Ferguson G . Goals of COPD treatment: Focus on symptoms and exacerbations. Respir Med. 2020; 166:105938. DOI: 10.1016/j.rmed.2020.105938. View

13.

Prins H, Duijkers R, Lutter R, Daniels J, van der Valk P, Schoorl M . Blood eosinophilia as a marker of early and late treatment failure in severe acute exacerbations of COPD. Respir Med. 2017; 131:118-124. DOI: 10.1016/j.rmed.2017.07.064. View

14.

Sivapalan P, Lapperre T, Janner J, Laub R, Moberg M, Bech C . Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial. Lancet Respir Med. 2019; 7(8):699-709. DOI: 10.1016/S2213-2600(19)30176-6. View

15.

Bafadhel M, Peterson S, De Blas M, Calverley P, Rennard S, Richter K . Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018; 6(2):117-126. DOI: 10.1016/S2213-2600(18)30006-7. View

16.

Pavord I, Lettis S, Locantore N, Pascoe S, Jones P, Wedzicha J . Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD. Thorax. 2015; 71(2):118-25. PMC: 4752631. DOI: 10.1136/thoraxjnl-2015-207021. View

17.

Yu S, Zhang J, Fang Q, Tong Z . Blood Eosinophil Levels and Prognosis of Hospitalized Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Am J Med Sci. 2021; 362(1):56-62. DOI: 10.1016/j.amjms.2021.02.013. View

18.

Hartl S, Breyer M, Burghuber O, Ofenheimer A, Schrott A, Urban M . Blood eosinophil count in the general population: typical values and potential confounders. Eur Respir J. 2020; 55(5). DOI: 10.1183/13993003.01874-2019. View

19.

Pascoe S, Locantore N, Dransfield M, Barnes N, Pavord I . Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015; 3(6):435-42. DOI: 10.1016/S2213-2600(15)00106-X. View

20.

Singh D, Kolsum U, Brightling C, Locantore N, Agusti A, Tal-Singer R . Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014; 44(6):1697-700. DOI: 10.1183/09031936.00162414. View